RMC-5845

RMC-5845 is an orally bioavailable, highly selective small‑molecule inhibitor of son of sevenless homolog 1 (SOS1), a key guanine nucleotide exchange factor that catalyzes conversion of RAS from its inactive GDP‑bound state (RAS(OFF)) to the active GTP‑bound state (RAS(ON)).[1][4][11] Developed by Revolution Medicines as a RAS Companion Inhibitor, RMC-5845 is intended for use in combination regimens for genetically defined, RAS‑addicted solid tumors (such as KRAS‑mutant cancers), where SOS1 blockade is expected to dampen upstream RAS activation and enhance the antitumor activity of direct RAS or downstream pathway inhibitors.[1][2][3][11] The program has been described as preclinical/IND‑enabling, with no active clinical trials publicly reported to date.[1][4][7][9][11]